(Q34984085)

5 August 2017

1 reference

title

Treatment of chronic hepatitis C: a systematic review (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

1 reference

2

Mark S Sulkowski

1 reference

5 August 2017

4

Michael S Torbenson

1 reference

5 August 2017

6

Eric B Bass

1 reference

5 August 2017

7

Kelly A Gebo

1 reference

5 August 2017

Geetanjali Chander

1

1 reference

5 August 2017

Mollie W Jenckes

series ordinal

3

1 reference

5 August 2017

H Franklin Herlong

series ordinal

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

36

1 reference

5 August 2017

issue

5 Suppl 1

1 reference

5 August 2017

page(s)

S135-44

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Hepatitis C: advances in diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Pharmacological treatment of alcohol dependence: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Long-term follow-up study of sustained biochemical responders with interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Estimating future hepatitis C morbidity, mortality, and costs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Natural history of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.37146

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.37146

1 reference

5 August 2017

1 reference